Vigil Neuroscience (VIGL) Jefferies 2024 Global Healthcare Conference summary

Company overview and differentiation

• Focuses on neuroimmunology breakthroughs to develop therapies for rare and common neurodegenerative diseases.

• Specializes in microglia, the brain's immune cells, aiming to enhance their protective functions.

• Clinical strategy targets genetically defined subpopulations to improve early signal detection.

• Only company with both small molecule and monoclonal antibody TREM2 agonists.

• Lead programs: VGL101 (monoclonal antibody, Phase 2 in ALSP) and VG-3927 (small molecule, targeting Alzheimer's).

Clinical program milestones and data

• Phase 1 data for VG-3927 (small molecule) expected mid-year, focusing on safety, tolerability, and biomarkers.

• Phase 2 interim data for VGL101 in ALSP due in Q3, expanding from 6 to 20 patients, with higher dose cohorts.

• Initial results show safety, target engagement, and slowing of disease progression in MRI biomarkers.

• Natural history study (ILLUMINATE) provides context and supports regulatory discussions.

• Flexibility in trial design allows for protocol adaptation based on emerging data.

Regulatory and market engagement

• Ongoing, iterative discussions with FDA, supported by both clinical and natural history data.

• Patient community actively engaging with FDA, including a recent listening session.

• ALSP market estimated at 10,000 patients in the US, with similar numbers internationally.

• $100 million in cash as of March, sufficient to fund operations into the second half of next year.